Cancer News Roundup: Parton's Death, Mammogram Warning, Ifosfamide Shortage

Representatives confirmed that entertainer Dolly Parton died of cancer, though the specific type was not disclosed, and her sister noted she volunteered for experimental treatments. The FDA issued a safety alert about potential quality issues with mammograms at a California facility, and the American Society of Clinical Oncology highlighted a critical shortage of the chemotherapy drug ifosfamide. Additional items included a settlement over false Medicare claims for skin cancer tests and a study on circulating tumor DNA predicting breast cancer recurrence.

The ifosfamide shortage has drawn attention from the American Society of Clinical Oncology, prompting the FDA to permit temporary imports from India. This highlights ongoing vulnerabilities in the generic drug supply chain that affect cancer treatment availability.

Several items touch on diagnostic and financial integrity. The FDA's mammogram safety alert at a California facility, the DermTech settlement over skin cancer test claims, and the Iowa lawyer's fraud case all point to concerns about accuracy and accountability in cancer care. Meanwhile, circulating tumor DNA testing showed promise for early breast cancer recurrence detection.